State Policy · LA
Louisiana Controlled Substance Law Restricts Hospital Access to Hemorrhage Medications
Louisiana's 2024 law reclassifying misoprostol and mifepristone as controlled substances has limited hospital access to these medications for emergency hemorrhage treatment in pregnant patients. The restrictions affect how quickly providers can obtain these drugs in non-abortion medical emergencies, creating delays in time-sensitive obstetric care. Other states are reportedly considering similar legislation. The law has operational implications for Medicaid-covered maternity care, where hemorrhage is a leading cause of maternal mortality and misoprostol is a standard emergency treatment.
Why it mattersMedicaid covers approximately 42% of births nationally, and restricted access to emergency hemorrhage medications increases maternal mortality risk for a predominantly Medicaid-enrolled patient population.